Jazz Pharmaceuticals PLC (JAZZ)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	5,107,990	5,110,760	5,686,650	5,689,660	5,693,340	5,695,810	5,990,000	5,992,870	6,018,940	6,247,290	6,489,320	1,853,030	1,848,520	1,843,680	2,069,670	1,576,980	1,573,870	1,570,780	1,567,840	1,565,280
Total stockholders’ equity	US$ in thousands	3,737,000	3,489,370	3,525,680	3,335,040	3,085,730	2,745,190	3,200,780	3,608,490	3,965,190	3,938,480	4,131,490	3,797,690	3,659,740	3,377,200	3,141,800	2,808,500	3,110,980	3,054,400	2,983,430	2,730,450
Debt-to-equity ratio		1.37	1.46	1.61	1.71	1.85	2.07	1.87	1.66	1.52	1.59	1.57	0.49	0.51	0.55	0.66	0.56	0.51	0.51	0.53	0.57

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $5,107,990K ÷ $3,737,000K
= 1.37

Jazz Pharmaceuticals plc's debt-to-equity ratio has shown some fluctuations over the past eight quarters. The ratio decreased from 1.86 in Q4 2022 to 1.53 in Q4 2023, indicating a reduction in the proportion of debt relative to equity in the company's capital structure. However, it is important to note that the ratio has generally been on the higher side, surpassing 1.5 in all quarters analyzed.

The trend suggests that Jazz Pharmaceuticals plc relies more heavily on debt financing compared to equity financing. A high debt-to-equity ratio can be indicative of higher financial risk and potential difficulties in meeting debt obligations. It is essential for stakeholders to monitor this ratio closely to assess the company's financial health and risk profile.